Departments of Medicine (Cardiovascular Medicine) (Y.X., A.C.O., Y.J., K.A.M., J.H.), Yale University, New Haven, CT.
Pharmacology (Y.X., A.C.O., Y.J., K.A.M.), Yale University, New Haven, CT.
Circulation. 2019 Jan 29;139(5):679-693. doi: 10.1161/CIRCULATIONAHA.118.034615.
Vascular smooth muscle cells (SMCs) synthesize extracellular matrix (ECM) that contributes to tissue remodeling after revascularization interventions. The cytokine transforming growth factor β (TGF-β) is induced on tissue injury and regulates tissue remodeling and wound healing, but dysregulated signaling results in excess ECM deposition and fibrosis. The LIM (Lin11, Isl-1 & Mec-3) domain protein LIM domain only 7 (LMO7) is a TGF-β1 target gene in hepatoma cells, but its role in vascular physiology and fibrosis is unknown.
We use carotid ligation and femoral artery denudation models in mice with global or inducible smooth muscle-specific deletion of LMO7, and knockout, knockdown, overexpression, and mutagenesis approaches in mouse and human SMC, and human arteriovenous fistula and cardiac allograft vasculopathy samples to assess the role of LMO7 in neointima and fibrosis.
We demonstrate that LMO7 is induced postinjury and by TGF-β in SMC in vitro. Global or SMC-specific LMO7 deletion enhanced neointimal formation, TGF-β signaling, ECM deposition, and proliferation in vascular injury models. LMO7 loss of function in human and mouse SMC enhanced ECM protein expression at baseline and after TGF-β treatment. TGF-β neutralization or receptor antagonism prevented the exacerbated neointimal formation and ECM synthesis conferred by loss of LMO7. Notably, loss of LMO7 coordinately amplified TGF-β signaling by inducing expression of Tgfb1 mRNA, TGF-β protein, αv and β3 integrins that promote activation of latent TGF-β, and downstream effectors SMAD3 phosphorylation and connective tissue growth factor. Mechanistically, the LMO7 LIM domain interacts with activator protein 1 transcription factor subunits c-FOS and c-JUN and promotes their ubiquitination and degradation, disrupting activator protein 1-dependent TGF-β autoinduction. Importantly, preliminary studies suggest that LMO7 is upregulated in human intimal hyperplastic arteriovenous fistula and cardiac allograft vasculopathy samples, and inversely correlates with SMAD3 phosphorylation in cardiac allograft vasculopathy.
LMO7 is induced by TGF-β and serves to limit vascular fibrotic responses through negative feedback regulation of the TGF-β pathway. This mechanism has important implications for intimal hyperplasia, wound healing, and fibrotic diseases.
血管平滑肌细胞(SMCs)合成细胞外基质(ECM),有助于血管再通干预后的组织重塑。细胞因子转化生长因子β(TGF-β)在组织损伤时被诱导,并调节组织重塑和伤口愈合,但信号转导失调会导致 ECM 过度沉积和纤维化。LIM(Lin11、Isl-1 和 Mec-3)结构域蛋白 LIM 结构域仅 7(LMO7)是肝癌细胞中 TGF-β1 的靶基因,但它在血管生理学和纤维化中的作用尚不清楚。
我们使用颈动脉结扎和股动脉剥脱模型,在小鼠中进行全局或诱导性平滑肌特异性 LMO7 缺失,以及在小鼠和人 SMC 中进行基因敲除、基因敲低、过表达和突变,以及人动静脉瘘和心脏同种异体移植物血管病变样本,以评估 LMO7 在新内膜和纤维化中的作用。
我们证明 LMO7 在体外 SMC 中损伤后和 TGF-β诱导。在血管损伤模型中,全局或 SMC 特异性 LMO7 缺失增强了新内膜形成、TGF-β信号、ECM 沉积和增殖。人源和鼠源 SMC 中 LMO7 功能丧失增强了 TGF-β 治疗前后 ECM 蛋白的表达。TGF-β 中和或受体拮抗作用可预防 LMO7 缺失引起的新内膜形成和 ECM 合成加剧。值得注意的是,LMO7 通过诱导 Tgfb1 mRNA、TGF-β 蛋白、αv 和 β3 整合素的表达,促进潜伏 TGF-β的激活,以及下游效应物 SMAD3 磷酸化和结缔组织生长因子的表达,协调放大 TGF-β 信号。机制上,LMO7 的 LIM 结构域与激活蛋白 1 转录因子亚基 c-FOS 和 c-JUN 相互作用,并促进它们的泛素化和降解,破坏激活蛋白 1 依赖性 TGF-β 自动诱导。重要的是,初步研究表明,LMO7 在人类内膜增生性动静脉瘘和心脏同种异体移植物血管病变样本中上调,并与心脏同种异体移植物血管病变中的 SMAD3 磷酸化呈负相关。
LMO7 由 TGF-β诱导,通过负反馈调节 TGF-β 途径来限制血管纤维化反应。该机制对内膜增生、伤口愈合和纤维化疾病具有重要意义。